A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients

Por Hakobyan, Liana, Haaijer-Ruskamp, Flora M, de Zeeuw, Dick, Dobre, Daniela, Denig, Petra
Publicado em 2011

Does the European Clinical Trials Directive really improve clinical trial approval time?

Por Lambers Heerspink, Hiddo J, Dobre, Daniela, Hillege, Hans L, Grobbee, Diederick E, de Zeeuw, Dick
Publicado em 2008

Effectiveness of β-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?

Por Dobre, Daniela, DeJongste, Mike J L, Lucas, Carolien, Cleuren, Ger, van Veldhuisen, Dirk J, Ranchor, Adelita V, Haaijer-Ruskamp, Flora
Publicado em 2007

Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial

Por Dobre, Daniela, Zannad, Faiez, Keteyian, Steven J., Stevens, Susanna R., Rossignol, Patrick, Kitzman, Dalane W., Landzberg, Joel, Howlett, Jonathan, Kraus, William E., Ellis, Stephen J.
Publicado em 2013

The contribution of observational studies to the knowledge of drug effectiveness in heart failure

Por Dobre, Daniela, van Veldhuisen, Dirk J, deJongste, Mike J L, van Sonderen, Eric, Klungel, Olaf H, Sanderman, Robbert, Ranchor, Adelita V, Haaijer-Ruskamp, Flora M
Publicado em 2007